Phaseline

Companies › Precise Bio

Precise Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Precise Vision Endothelial Keratoplasty (PVEK) Implant
Tissue-engineered corneal endothelial implant consisting of human collagen scaffold and co
–Phase 1Corneal EdemaMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07325097Precise Vision Endothelial Keratoplasty (PVEK) ImplantPhase 1Corneal EdemaOphthalmologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.